Canaccord raised the firm’s price target on Corcept Therapeutics (CORT) to $140 from $137 and keeps a Buy rating on the shares. The firm met with management and updated its model to reflect the company’s distribution fix and its oncology commercial infrastructure that they are building out to include the EU as well.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on CORT:
- Corcept Therapeutics’ New Drug Application Accepted by FDA
- Corcept Therapeutics announces FDA acceptance of relacorilant NDA
- Corcept Therapeutics’ Miricorilant Study: A Potential Game-Changer for Liver Disease Treatment
- Corcept Therapeutics’ MOMENTUM Study: A Closer Look at Hypercortisolism in Resistant Hypertension
- Corcept Therapeutics Advances Liver Fat Reduction Study with Miricorilant